Figure 5.

Compound screening identifies SB525334, an ALK5 inhibitor, which ameliorates BLM-induced abnormality of epithelial cells in FD-AOs

(A) Schematic overview of compound treatment.

(B) Heatmap indicating Z scores of the SASP factors (IL6, CXCL8, SERPINE1) and PATS markers (SFN, GDF15, MMP7). Raw data were measured by qRT-PCR in whole organoids. The Z scores were calculated using the averaged value of fold change relative to the BLM-treated sample in each experiment (n ≥ 3 independent experiments).

(C) Expression of the SASP factors in EpCAM⁺ and EpCAM⁻ cells separated from FD-AOs measured by qRT-PCR and normalized to each control.

(D) Expression of the PATS markers in EpCAM⁺ cells separated from FD-AOs.

Data are presented as mean ± SEM (n = 8 independent experiments). One-way ANOVA with Dunnett’s multiple comparisons test: ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001; ns, not significant.